Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Profit After Tax (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Profit After Tax for 15 consecutive years, with $153.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax rose 49.08% year-over-year to $153.7 million, compared with a TTM value of $478.6 million through Dec 2025, up 40.23%, and an annual FY2025 reading of $478.6 million, up 40.23% over the prior year.
  • Profit After Tax was $153.7 million for Q4 2025 at Neurocrine Biosciences, down from $209.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $209.5 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
  • Average Profit After Tax over 4 years is $77.8 million, with a median of $83.1 million recorded in 2023.
  • The sharpest move saw Profit After Tax surged 156.66% in 2024, then tumbled 81.8% in 2025.
  • Year by year, Profit After Tax stood at $22.5 million in 2021, then skyrocketed by 556.44% to $147.7 million in 2023, then tumbled by 30.2% to $103.1 million in 2024, then skyrocketed by 49.08% to $153.7 million in 2025.
  • Business Quant data shows Profit After Tax for NBIX at $153.7 million in Q4 2025, $209.5 million in Q3 2025, and $107.5 million in Q2 2025.